Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Operating Expenses (2024 - 2025)

Corvus Pharmaceuticals has reported Other Operating Expenses over the past 2 years, most recently at -$561000.0 for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$561000.0 for Q4 2025, up 28.08% from a year ago — trailing twelve months through Dec 2025 was -$3.0 million (up 4.16% YoY), and the annual figure for FY2025 was -$3.0 million, up 4.13%.
  • Other Operating Expenses for Q4 2025 was -$561000.0 at Corvus Pharmaceuticals, up from -$617000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for CRVS hit a ceiling of -$551000.0 in Q2 2024 and a floor of -$994000.0 in Q1 2024.